Numerous studies have consistently demonstrated long-term tumor responses from PD-1/PD-L1 inhibitors as compared with conventional chemotherapy in patients with PD-L1-positive tumors [46] or in some cancer types regardless of PD-L1 status [47]. Here, CD274 is linked to neoplasm.